Healthcare U.S. Community

Hims & Hers pushes beyond weight loss by stacking new services like lab testing, hormone care, and international expansion on top of its fast-growing subscription base. A reset in weight-loss supply and new partnerships change what the business can sell—and the big question is whether this broader platform can keep momentum while it keeps spending heavily.Read more

After a sharp sell-off, PROCEPT BioRobotics may be getting punished more for shifting how it reports sales than for any real slowdown in what doctors are doing. The bigger question is whether a feared medical procedure trend is actually a non-issue, and if upcoming results can reset sentiment.Read more

Hims & Hers grows from a telehealth brand into a broader online healthcare service that spans everything from primary care to mental health and weight management. The big question is whether it can keep growing while handling changing rules around popular weight-loss treatments and rising competition from much larger players.Read more

A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more

Doximity already reaches a huge share of working doctors, and that kind of trusted, daily-use audience could unlock more ways to earn money over time. Its newer doctor-focused AI tools feel surprisingly strong, but the big question is whether those tools matter as more doctors work for large employers instead of running their own practices.Read more

BrightSpring’s growth story may look like home health at first glance, but the real engine is its specialty and long-term care pharmacy business, where patients rarely switch providers once treatment starts. As the company finishes cleanup work from past restructuring, improving efficiency and lower debt could change how the market views the business.Read more

The Hook: A Massive Valuation Disconnect While the market has pinned NexGel (NXGL) to its 52-week lows near $0.58 , the underlying business has just undergone a fundamental "rebirth." According to Simply Wall St’s intrinsic value model, the stock is currently 86.5% undervalued , with a fair value estimate of $4.30. This creates a rare setup where the market cap ($5M) is significantly lower than the company's projected annual revenue.Read more

$BLCO & $COO. The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure By a Retail Investor and Portfolio Manager (Opinion) --- I.Read more

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more